Are Bikrona tablets expensive? Can it be reimbursed?

Biktarvy/Biktarvy, as a single-tablet triple regimen that has been widely used around the world in recent years, has become the first-line choice for many patients and doctors. Its application value is mainly reflected in two aspects: first, for initial treatment of AIDS patients, it can quickly and permanently inhibit viral replication, reducing the complexity caused by multi-drug combination; second, for long-term management of patients, its simple one-a-day regimen greatly improves compliance and reduces the risk of drug resistance due to missed doses or drug withdrawals. Overseas clinical practice shows that Biktarvy performs well in terms of virological control and tolerability, and is an important representative in line with modern treatment concepts.

In China, Bituvi has been officially launched and included in the national medical insurance directory, which is of great significance to the patient group. In the early days, the drug was relatively expensive, placing a financial burden on many patients. However, with the negotiation of medical insurance and the implementation of policies, the current medical insurance price of a box of 30 tablets has dropped to more than one thousand yuan. The proportion of patients paying out-of-pocket after reimbursement has been greatly reduced, and the financial pressure has been significantly reduced. This policy has greatly improved the accessibility of drugs, allowing more people to receive long-term standardized treatment.

At the same time, there are also generic Bituvit drugs that are officially launched in the Indian market. The price is even lower, about a few hundred yuan per box, and the drug ingredients are consistent with the original drug. This provides a choice for some patients who are under financial pressure or need to purchase drugs through overseas channels. However, considering the source of drugs, quality control and follow-up system, purchasing original drugs through formal channels is still a safer way.

In addition to the price issue,Biktarvy’s long-term application also emphasizes patient education and medical follow-up. Even if a drug is affordable, patients still need to take it on time and cooperate with regular check-ups to get the most out of the drug. As medical insurance coverage increases and market competition intensifies, drug prices are expected to be further optimized in the future, allowing more patients to enjoy advanced treatments at reasonable costs.

Reference materials:https://www.biktarvy.com/